Greg Divis News Today

Avadel Pharmaceuticals shared updates on the performance and reception of its new narcolepsy medication, Lumryz.

08.01.2024 - - Approximately $19 million and $28 million of net revenue from sales of LUMRYZ estimated for the fourth quarter and full year 2023, respectively - - Generated continued robust demand for LUMRYZ with greater than 1,900 patients enrolled in ... Seite 1

Avadel Pharmaceuticals has submitted an sNDA to the FDA for Lumryz for treatment of cataplexy or EDS in the pediatric narcolepsy population. 

Operator: Greetings, and welcome to the Avadel Pharmaceuticals Third Quarter 2023 Earnings Call. [Operator Instructions].

By Denny Jacob American depositary receipts of Avadel Pharmaceuticals rose 19% to $12.34 on revenue growth powered by sales of Lumryz in the third quarter....

-- $7.0 million in third quarter LUMRYZ™ net revenue from U.S. commercial launch -- -- Generated robust demand for LUMRYZ with greater than 1,000 patients enrolled in RYZUPTM and more than 400 patients initiating therapy as of September 30 -- -- LUMRYZ to be added to preferred position for CVS commercial formularies effective January 1, 2024 -- -- Submitted sNDA for LUMRYZ in pediatric narcolepsy population on November 7th -- -- Management to host a conference call today at 8:30 a.m. ET -...

Avadel provided a Q2 corporate update detailing the progress following Lumryz's approval by the FDA during the period.

-- Successfully commenced U.S. commercial launch of LUMRYZ™-- -- Received final FDA approval for LUMRYZ with orphan drug exclusivity granted through May 1, 2030 -- -- Significant early progress on payor coverage, prescriber certifications and patient enrollments -- -- Management to host a conference call today at 8:30 a.m. ET -- DUBLIN, Ireland, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to tra...

By Denny Jacob Avadel Pharmaceuticals intends to intervene in a lawsuit filed by Jazz Pharmaceuticals against the U.S. Food and Drug Administration, Avadel Chief Executive Greg Divis said. Ireland-based biopharmaceutical company Jazz Pharmaceu...

By Denny Jacob Avadel Pharmaceuticals intends to intervene in a lawsuit filed by Jazz Pharmaceuticals against the U.S. Food and Drug Administration, Avadel...